Impact of plaque morphology on creatine kinase-MB elevation in patients with elective stent implantation

Int J Cardiol. 2011 Jan 7;146(1):80-5. doi: 10.1016/j.ijcard.2010.06.010. Epub 2010 Jul 1.

Abstract

Backgrounds: The association between percutaneous coronary intervention (PCI) and subsequent myonecrosis has been widely recognized, and worse prognosis has been reported among patients with elevated post-PCI biomarkers. We used optical coherence tomography (OCT) to study the relationship between pre-PCI plaque morphology and post-PCI creatine kinase-MB (CK-MB) elevation.

Methods: One hundred and twenty-five patients with normal pre-PCI CK-MB levels underwent OCT examination before nonemergency stent implantation. Patients were divided into two groups according to the presence (Group CK, n=35) or absence (Group NCK, n=90) of post-PCI CK-MB elevation ≥ upper limit of the normal range. Clinical and the OCT findings were compared between the two groups.

Results: Elevated CK-MB levels was observed in 35 patients (28%). The CK-MB elevation was associated with elevated white blood cell count, type B2/C lesions, the presence of thin cap fibroatheroma (TCFA), plaque rupture, and lipid quadrants. In the multivariate analysis, the presence of TCFA (OR 4.68, 95% CI 1.88-11.64, p=0.001) and type B2/C lesions (OR 4.20, 95% CI 1.30-13.59, p=0.02) were independent predictors of post-PCI CK-MB elevation.

Conclusions: TCFA and angiographically complex lesion morphology can predict post-PCI CK-MB elevation in patients treated with elective stent implantation. OCT may be useful in stratifying the risk for nonemergency stent implantation.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Angioplasty, Balloon, Coronary / adverse effects
  • Biomarkers / blood
  • Creatine Kinase, MB Form / blood*
  • Elective Surgical Procedures* / adverse effects
  • Female
  • Humans
  • Male
  • Middle Aged
  • Plaque, Atherosclerotic / blood*
  • Plaque, Atherosclerotic / diagnostic imaging*
  • Prospective Studies
  • Stents* / adverse effects
  • Tomography, Optical Coherence* / methods
  • Treatment Outcome
  • Ultrasonography

Substances

  • Biomarkers
  • Creatine Kinase, MB Form